Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientifi...( DUROS(R) continuous delivery of exena...)

DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day treatment

NEW ORLEANS, June 8 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented results from the first clinical study of ITCA 650 (DUROS(R) continuous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in New Orleans, LA (June 5-9, 2009). Results of the phase 1b study demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period. Other important results from the study were substantial reductions in postprandial glucose (PPG), HbA1c and body weight.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"This study was designed to evaluate a more effective and patient-friendly approach to deliver exenatide therapy for the treatment of type 2 diabetes," said K. Alice Leung, President & CEO of Intarcia Therapeutics, Inc. "ITCA 650 ensures that patients receive the benefits of an optimized dose of exenatide immediately upon initiation of treatment, and it continuously provides consistent, round-the-clock control of blood glucose without requiring patients to inject themselves."

The phase 1b dose ranging study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among 44 type 2 diabetes patients (10-12 patients/dose arm) on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included four dose arms to which patients were randomized to receive 10 mcg/day, 20 mcg/day, 40 mcg/day or 80 mcg/day exenatide for a 28 day treatment duratio
'/>"/>